



| 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000   | 2001   | 2002   | 2003   | 2004   | 2005   | 2006   | 2007   | 2008   | 2009   | 2010   | © VALUE LINE PUB., INC.           | 12-14  |
|------|------|------|------|------|------|------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--|--------|-----------------------------------|--------|
| --   | --   | --   | --   | --   | --   | --   | 3.42   | 4.13   | 4.87   | 5.99   | 7.85   | 8.49   | 11.09  | 12.25  | 13.03  | 16.50  | 18.65  | Sales per sh                      | 23.25  |
| --   | --   | --   | --   | --   | --   | --   | .48    | .77    | .96    | 1.36   | 1.94   | 2.13   | 3.03   | 3.22   | 3.37   | 4.10   | 5.05   | "Cash Flow" per sh                | 6.15   |
| --   | --   | --   | --   | --   | --   | --   | .29    | .53    | .76    | 1.07   | 1.42   | 1.59   | 2.30   | 2.38   | 2.86   | 3.30   | 4.15   | Earnings per sh <sup>B</sup>      | 5.10   |
| --   | --   | --   | --   | --   | --   | --   | .06    | .07    | .10    | .16    | .20    | .27    | .31    | .39    | .49    | .59  | .60    | Div'ds Decl'd per sh <sup>C</sup> | .64    |
| --   | --   | --   | --   | --   | --   | --   | .17    | .23    | .31    | .38    | .51    | .50    | .51    | .71    | .80    | .85  | .90    | Cap'l Spending per sh             | .90    |
| --   | --   | --   | --   | --   | --   | --   | 2.25   | 2.74   | 3.54   | 6.02   | 8.81   | 9.77   | 14.70  | 17.87  | 19.15  | 21.70  | 25.50  | Book Value per sh <sup>D</sup>    | 38.95  |
| --   | --   | --   | --   | --   | --   | --   | 511.67 | 503.40 | 517.20 | 546.80 | 611.40 | 618.60 | 758.00 | 768.00 | 851.00 | 858.00                                       | 858.00 | Common Shs Outst'g <sup>E</sup>   | 860.00 |
| --   | --   | --   | --   | --   | --   | --   | 46.5   | 28.9   | 21.4   | 23.7   | 21.1   | 21.0   | 15.9   | 17.1   | 15.8   | <i>Bold figures are Value Line estimates</i> |        | Avg Ann'l P/E Ratio               | 22.0   |
| --   | --   | --   | --   | --   | --   | --   | 3.02   | 1.48   | 1.17   | 1.35   | 1.11   | 1.12   | .86    | .91    | .95    |  |        | Relative P/E Ratio                | 1.45   |
| --   | --   | --   | --   | --   | --   | --   | .4%    | .5%    | .6%    | .6%    | .7%    | .8%    | .9%    | 1.0%   | 1.1%   |  |        | Avg Ann'l Div'd Yield             | .6%    |

| CAPITAL STRUCTURE as of 3/31/09 |                             | 2007   | 2008   | 3/31/09 | BUSINESS: |        |
|---------------------------------|-----------------------------|--------|--------|---------|-----------|--------|
| Total Debt                      | \$8,419 mill.               | 1749.9 | 2077.4 | 2518.6  | 3276.4    | 4798.9 |
| LT Debt                         | \$5,063 mill.               | 95.0   | 109.1  | 86.8    | 127.7     | 220.4  |
| Leases, Uncapitalized           | Annual rentals \$69.0 mill. | 148.4  | 278.2  | 410.3   | 617.8     | 964.6  |
| No Defined Benefit Pension Plan |                             | 28.6%  | 18.7%  | 17.0%   | 20.0%     | 22.2%  |
| Pfd Stock                       | None                        | 8.5%   | 13.4%  | 16.3%   | 18.9%     | 20.1%  |
| Common Stock                    | 853,000,000 shs.            | 825.1  | 1439.8 | 1377.2  | 2021.5    | 1997.6 |
| MARKET CAP:                     | \$42.0 billion (Large Cap)  | 813.9  | 1246.9 | 1152.2  | 815.4     | 1728.4 |
| CURRENT POSITION (SMILL.)       |                             | 1151.3 | 1380.7 | 1829.4  | 3289.4    | 5388.9 |
| Cash Assets                     | 2875                        | 1907   | 2400   | 2875    | 3276.4    | 4798.9 |
| Receivables                     | 3546                        | 4653   | 4134   | 3546    | 4798.9    | 5250.4 |
| Inventory (Avg Cst)             | 2440                        | 3396   | 3211   | 2440    | 3276.4    | 8408.0 |
| Other                           | 998                         | 1470   | 1395   | 998     | 3276.4    | 9408   |
| Current Assets                  | 9859                        | 11426  | 11140  | 9859    | 3276.4    | 11085  |
| Accts Payable                   | 1383                        | 2244   | 2060   | 1383    | 3276.4    | 14150  |
| Debt Due                        | 1841                        | 2906   | 3356   | 1841    | 3276.4    | 16000  |
| Other                           | 2147                        | 3331   | 3154   | 2147    | 3276.4    | 14150  |
| Current Liab.                   | 5371                        | 8481   | 8570   | 5371    | 3276.4    | 16000  |

**TEVA PHARMACEUTICAL IS PERFORMING FAIRLY WELL.** Although no major product launches were made in the March quarter, the generic drug maker was off to a decent start in 2009, thanks to record-level *Copaxone* sales, strong sales of other key drugs, including *Azilect* and *ProAir* (respiratory product), global expansion, and contributions from the recently acquired Barr business. Admittedly, foreign exchange headwinds tempered top- and bottom-line gains. But, excluding \$0.20 in charges, share net in the initial period managed to come in a penny ahead of our call and the year-ago tally, on a higher share count.

| Cal-endar | QUARTERLY SALES (\$ mill.) |        |        |        | Full Year |
|-----------|----------------------------|--------|--------|--------|-----------|
|           | Mar.31                     | Jun.30 | Sep.30 | Dec.31 |           |
| 2006      | 1672.5                     | 2172.4 | 2285.7 | 2277.4 | 8408.0    |
| 2007      | 2080                       | 2386   | 2366   | 2576   | 9408      |
| 2008      | 2572                       | 2823   | 2842   | 2848   | 11085     |
| 2009      | 3147                       | 3500   | 3650   | 3853   | 14150     |
| 2010      | 3700                       | 3900   | 4100   | 4300   | 16000     |

  

| Cal-endar | EARNINGS PER SHARE <sup>B</sup> |        |        |        | Full Year |
|-----------|---------------------------------|--------|--------|--------|-----------|
|           | Mar.31                          | Jun.30 | Sep.30 | Dec.31 |           |
| 2006      | .37                             | .66    | .74    | .53    | 2.30      |
| 2007      | .42                             | .63    | .64    | .69    | 2.38      |
| 2008      | .70                             | .68    | .72    | .76    | 2.86      |
| 2009      | .71                             | .77    | .87    | .95    | 3.30      |
| 2010      | .95                             | 1.00   | 1.05   | 1.15   | 4.15      |

  

| Cal-endar | QUARTERLY DIVIDENDS PAID <sup>C</sup> |        |        |        | Full Year |
|-----------|---------------------------------------|--------|--------|--------|-----------|
|           | Mar.31                                | Jun.30 | Sep.30 | Dec.31 |           |
| 2005      | .069                                  | .068   | .066   | .063   | .27       |
| 2006      | .072                                  | .074   | .077   | .078   | .30       |
| 2007      | .094                                  | .099   | .095   | .101   | .39       |
| 2008      | .122                                  | .135   | .125   | .111   | .49       |
| 2009      | .14                                   | .15    |        |        |           |

**We look for share profits to rise 15% in 2009 and 25% next year.** Much of what we envision is based on our expectation of sturdy *Copaxone* sales and ongoing global market-share gains, as well as generic launches of certain key branded drugs. Indeed, **generic drug growth opportunities abound.** As of the end of April, Teva had 197 product applications pending FDA approval (with the branded versions generating annual sales of \$109 billion). It also had more than 3,400 applications awaiting approval for marketing authorization in 30 European countries. **Meanwhile, the Barr addition should prove to be a benefit, too,** thanks to Barr's strength in women's healthcare (i.e., oral contraceptives) and its wide geographic reach. And with the newcomer's integration moving ahead of schedule, cost synergies seem likely to exceed \$400 million over three years (which is well above the original estimate of \$300 million). **Teva's sizable expansion potential augurs well for the long term,** especially with Barr in the fold. Not only has the company's presence been bolstered in the U.S. and in key markets across Central and Eastern Europe, but it now has a more diverse and extensive drug portfolio and pipeline. Biologics is one avenue of growth we think Teva will pursue in the coming years. **These ADRs remain ranked Highest for Timeliness,** based on positive price and earnings momentum of late and a favorable near-term outlook. **Capital gains possibilities to 2012-2014 are substantial here, as well,** based on our earnings projections for that time frame.

|  |   |   |   |   |
|--|---|---|---|---|
| (A) All figures in US\$. Based on U.S. GAAP. | (B) Diluted earnings. Qly. EPS may not add to total due to rounding. Excl. nonrec. gains/(charges): '03, \$0.11; '04, (\$0.92); '06 (\$1.61); '08, (\$2.08); Q1'09, (\$0.20). Next earnings report due early Aug. | (C) Dividends historically paid early March, early June, late August, and mid-December. | (D) Incl. intangibles. At 12/31/08: \$16,878 mill., \$19.83/sh. | (E) In millions, adjusted for stock splits. Each ADR equals one common share. |
|--|---|---|---|---|

**To subscribe call 1-800-833-0046.**